Subcutaneous Amivantamab in Everyday Practice

Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute says he sees no remaining role for intravenous amivantamab in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), with subcutaneous administration taking 10 to 15 minutes and easing chair time and scheduling. He argues that every regimen carries a learning curve and that chemotherapy feels comfortable only because oncologists have used it for decades, so clinicians should not abandon an effective regimen because they are uneasy managing its toxicity. Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center notes that toxicity is front-loaded and that dose reductions and interruptions keep patients on treatment. Dr Devarakonda adds that avoiding a port matters to patients given the cosmetic effect, discomfort and infection risk, and Dr Rodriguez notes that an oral plus subcutaneous regimen appeals to patients who want neither an intravenous line nor chemotherapy, provided the first weeks include close support.